Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:approves |
gptkb:2015
gptkb:Canada gptkb:Japan gptkb:South_Korea gptkb:United_States |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Radicut
|
| gptkbp:casnumber |
57413-84-0
|
| gptkbp:chemical_formula |
C10 H10 N2 O5 S
|
| gptkbp:class |
phenolic compound
|
| gptkbp:clinical_trial |
Phase II
Phase III |
| gptkbp:clinical_use |
stroke patients
ALS patients patients with neurodegenerative disorders |
| gptkbp:composed_by |
synthesis from 2-amino-3-methylbenzenesulfonic acid
synthesis from 2-methyl-2-(4-nitrophenyl)propane-1,3-diol |
| gptkbp:discovered_by |
gptkb:Mitsubishi_Tanabe_Pharma_Corporation
|
| gptkbp:dissolved |
soluble in water
soluble in ethanol |
| https://www.w3.org/2000/01/rdf-schema#label |
edaravone
|
| gptkbp:invention |
patented
|
| gptkbp:marketed_as |
gptkb:Radicava
|
| gptkbp:mechanism_of_action |
antioxidant
free radical scavenger |
| gptkbp:related_products |
gptkb:MCI-186
Mitsubishi Tanabe Pharma's other drugs |
| gptkbp:research_areas |
gptkb:neurodegenerative_diseases
oxidative stress neuroprotection stroke recovery |
| gptkbp:route_of_administration |
oral
intravenous |
| gptkbp:side_effect |
gptkb:anemia
dizziness headache nausea injection site reactions thrombocytopenia hypersensitivity reactions liver function abnormalities |
| gptkbp:storage |
store at room temperature
protect from light |
| gptkbp:used_for |
treatment of acute ischemic stroke
treatment of amyotrophic lateral sclerosis |
| gptkbp:weight |
250.26 g/mol
|
| gptkbp:bfsParent |
gptkb:ALS
gptkb:amyotrophic_lateral_sclerosis gptkb:neurodegenerative_diseases |
| gptkbp:bfsLayer |
4
|